We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 68.00 | 0.55% | 12,332.00 | 12,342.00 | 12,346.00 | 12,388.00 | 12,256.00 | 12,268.00 | 1,329,916 | 16:35:26 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 32.13 | 191.36B |
From May 2019 to May 2024
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) and Merck & Co. Inc. (MRK) on Friday said the U.S. Food and Drug Administration has approved a new tablet form of the ovarian cancer treatment Lynparza.
The two drug companies are collaborating on developing and marketing Lynparza, which was initially developed by AstraZeneca.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
August 18, 2017 02:34 ET (06:34 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
